Back to Search
Start Over
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
- Source :
-
Cancer [Cancer] 2013 Jul 15; Vol. 119 (14), pp. 2639-44. Date of Electronic Publication: 2013 Apr 15. - Publication Year :
- 2013
-
Abstract
- Background: There is no standard treatment for progressive epithelioid hemangioendothelioma (EHE). To investigate the significant vascularization of EHE, the activity/toxicity of sorafenib in patients with progressive EHE was explored.<br />Methods: In this multicenter, 1-stage, phase 2 trial of sorafenib (800 mg daily), the primary endpoint, which was chosen by default, was the 9-month progression-free rate. All patients had documented progressive disease at the time of study entry.<br />Results: Fifteen patients were enrolled between June 2009 and February 2011. The median age was 57 years (range, 31-76 years), and the ratio of men to women was 9:6. The performance status was zero in 10 patients and 1 in 5 patients. Twelve patients had metastases, mainly in the lung (12 patients), liver (5 patients), and bone (3 patients). Five patients had received prior chemotherapy (doxorubicin in 5 patients and taxane in 3 patients). The median sorafenib treatment duration was 124 days (range, from 27 to >271 days). Seven patients required dose reductions or transient treatment discontinuation. The 9-month progression-free rate was 30.7% (4 of 13 patients). The 2-month, 4-month, and 6-month progression-free rate was 84.6% (11 of 13 patients), 46.4% (6 of 13 patients), and 38.4% (5 of 13 patients), respectively. Two partial responses were observed that lasted 2 months and 9 months.<br />Conclusions: Further clinical trials exploring sorafenib as treatment of progressive EHE are needed.<br /> (© 2013 American Cancer Society.)
- Subjects :
- Adult
Aged
Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Disease Progression
Disease-Free Survival
Drug Administration Schedule
Female
France
Head and Neck Neoplasms drug therapy
Hemangioendothelioma, Epithelioid secondary
Humans
Liver Neoplasms drug therapy
Male
Middle Aged
Niacinamide administration & dosage
Niacinamide adverse effects
Niacinamide therapeutic use
Phenylurea Compounds administration & dosage
Phenylurea Compounds adverse effects
Protein Kinase Inhibitors therapeutic use
Rare Diseases
Sorafenib
Time Factors
Treatment Outcome
Antineoplastic Agents therapeutic use
Hemangioendothelioma, Epithelioid drug therapy
Niacinamide analogs & derivatives
Phenylurea Compounds therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1097-0142
- Volume :
- 119
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 23589078
- Full Text :
- https://doi.org/10.1002/cncr.28109